SHILPA
GenericsSHILPA is a generic drug manufacturer focused on Oncology, Gastroenterology.
SHILPA's Key Drugs
SHILPA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
SHILPA's Recent FDA Approvals
SHILPA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SHILPA's Therapeutic Areas
SHILPA's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SHILPA's Top Competitors
SHILPA's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SHILPA Pipeline Snapshot
Active clinical trials for SHILPA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2015-12-22
- Latest
- 2025-08-04
- Applications
- 14